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Aim: To assess whether an intensive multifactorial treatment can reduce cognitive decrements and cognitive
decline in screen-detected type 2 diabetes.
Methods: The multinational ADDITION-study, a cluster-randomized parallel group trial in patients with screen-
detected type 2 diabetes, compared the effectiveness of intensive multifactorial treatment (IT; lifestyle advice
and strict regulation of metabolic parameters) with routine care (RC) on cardiovascular outcome. In The
Netherlands randomization was stratiﬁed according to practice organization. Allocation was concealed from
patients. The present study assessed the effect of IT on cognition through two neuropsychological assessments
(NPA) on two occasions. The assessments took place three and six years after the start of the intervention. Non-
diabetic controls served as reference group. The ﬁrst NPA was performed in 183 patients (IT: 97; RC: 86) and 69
controls. The second NPA was performed in 135 patients (IT: 71; RC: 64) and 55 controls. Primary outcomewas
a composite score, including the domains memory, information-processing speed and attention and executive
function. Comparisons between the treatment groups were performed with multi-level analyses.
Results: The ﬁrst NPA showed no differences between the treatment groups (mean difference composite z-score:
0.00; 95%-CI−0.16 to 0.16; IT vs RC). Over the next three years cognitive decline in the diabetic groups was
within the range of the reference group and did not differ between the treatment arms (difference decline
between diabetic groups−0.12;−0.24 to 0.01; IT vs RC).
Conclusions: Six years of IT in screen-detected type 2 diabetes had no beneﬁt on cognitive functioning over
RC.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
With the increasing incidence of type 2 diabetes, the prevalence of
associated complications increases as well. Besides well-known com-
plications, diabetes is also associated with decrements in learning and
memory, mental ﬂexibility and information-processing speed [1–3]
and with an increased risk of developing dementia [4–6]. These
cognitive decrements may already start to develop in pre-diabetic
stages [7] and are slowly progressive over the years [3].
The ADDITION study (Anglo–Danish–Dutch Study of Intensive
Treatment in People with Screen-Detected Diabetes in Primary
Care) [8], startedwith a population-based screening for type 2 diabetes.Sciences and Primary Care,
31, P.O. Box 85500, 3508 GA
+31 88 75 68099.
Koekkoek).
lsevier OA license.In those identiﬁed through screening, the effectiveness of intensive
multifactorial treatment on cardiovascular outcome was compared
with routine care according to national guidelines. At start of the
ADDITION-study it was known that patients with type 2 diabetes
have a twofold increased risk for developing dementia. Studies also
suggested that cognitive functioning in patients with type 2 diabetes
might beneﬁt from several months of improved glycemic control
[9,10]. It was unknown, however, what the rate of cognitive decline
was in people with early type 2 diabetes relative to controls. It was
also unknown whether we could prevent or diminish cognitive
decline in patients with screen-detected type 2 diabetes with for
example lifestyle advice and strict regulation of glucose levels,
blood pressure and lipid levels. Therefore we performed an add-on
study in a subgroup of patients of the ADDITION-Netherlands study
in which cognition was assessed on two occasions. The assessments
took place three and six years after start of the intervention. Our
aim was to investigate whether cognitive functioning beneﬁted
from intensive multifactorial treatment compared to routine care
after three years andwhether a further three years of intensive treatment
attenuated cognitive decline.
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2.1. Embedding
TheADDITION study is a pragmaticmultinational cluster-randomized
parallel group trial that compared screening plus intensivemultifactorial
treatment to screening and routine care. Mean follow-up was 5.3 years
[8]. Between 2002 and 2004, a population-based screening among 79
general practices in The Netherlands, screened 56 978 individuals
between 50 and 70 years for type 2 diabetes. In total 586 patients
were identiﬁed with type 2 diabetes according to the WHO-criteria
[11,12]. To avoid contamination, randomization was done on the level
of the general practice. Before screening, general practices were
therefore randomly allocated to intensive multifactorial treatment or
routine care using computer-generated random numbers, stratiﬁed
according to practice organization (single-handed vs. group practice)
(Fig. 1). Allocation was concealed from patients throughout the trial.
Exclusion criteria for participation in the intervention study were:
life expectancy of less than twelve months, being housebound, or
psychological or psychiatric problems that were likely to invalidate
informed consent [13]. Sixty-nine patients declined participation
and nineteen did not meet the eligibility criteria. Subsequently, 498
individuals were included in the Dutch part of the ADDITION interven-
tion study [14]. Patients started the intervention within six weeks after
screening.
2.2. Treatment protocols
Intensive multifactorial treatment consisted of lifestyle advice
regarding diet, physical activity and smoking and promotion of
protocol-driven strict regulation of metabolic parameters [8]. HbA1c
level had to be kept b53 mmol/mol (7.0%). Glucose-lowering therapy
with a biguanide, prandial glucose regulator or sulphonylurea had to
be altered when HbA1c was >48 mmol/mol (6.5%). Antihypertensive
treatment with an ACE inhibitor was prescribed if blood pressure was
>120/80 mmHg. When blood pressure was >135/85 mmHg calcium
channel blockers, thiazides or beta-blockers were added in a stepwise
approach. Patients receiving antihypertensive treatment were also
treated with aspirin 80 mg/day. Treatment with a statin was indicated if
total cholesterol was >3.5 mmol/L; dose needed to be increased when
total cholesterol was >5.0 mmol/L or >4.5 mmol/L in patients with
known cardiovascular disease (CVD). Although targets were speciﬁed
and classes of medication recommended, decisions about medication
were made by general practitioners and patients.
In the routine care group, general practitioners were only informed
about diagnostic test results. Patients received treatment according to
the current guidelines of the Dutch College of General Practitioners. At
start of ADDITION the guideline from 1999 was followed with target
levels for HbA1c, blood pressure and cholesterol below 69 mmol/mol
(8.5%), 150/85 mmHg and 5.0 mmol/L respectively [15]. In 2006 a
new guidelinewas introducedwith stricter goals for HbA1c and systolic
blood pressure respectively being below 53 mmol/mol (7.0%) and
140 mmHg [16]. Furthermore a statinwas advised for almost all patients.
Patients with CVD received aspirin 80 mg/day. Education and lifestyle
advice were also given.
2.3. Study population and cognitive assessment
In the present add-on study, patients were invited to participate
in a project in which cognition was assessed. We intended to include
approximately one hundred patients per treatment group, allowing to
detect a difference between the groups of an effect size of 0.3 standard
deviation units, which is considered to be a small to medium effect
in neuropsychological studies [17], with 80% power and α of 5%.
Patients were not eligible for the cognition sub-study if they had
a known psychiatric or neurological disorder that could inﬂuencecognitive functioning, history of alcohol or substance abuse or
were unable to complete a neuropsychological assessment (NPA).
Individuals with a previous non-invalidating stroke could participate.
Patients were randomly sampled from both groups, after their records
had been checked for exclusion criteria, and subsequently invited to
participate. A reference group of participants without diabetes was
recruited among spouses and acquaintances of the patients, matched
for age, sex and educational level. An additional exclusion criterion for
control participants was a fasting blood glucose >7.0 mmol/L. Because
some of the exclusion criteria only became evident at a face to face
interview (e.g. alcohol abuse), a second assessment against exclusion
criteria was done after the ﬁrst NPA by investigators unknown to
group allocation and cognitive status. The study was approved by the
medical ethics committee of the University Medical Center Utrecht,
The Netherlands. Written informed consent was obtained from all
participants.
2.4. Neuropsychological assessment
Participants underwent a detailed NPA on two occasions, in
2006–2007 and 2009–2010. Both NPAs consisted of twelve verbal
and nonverbal tasks addressing six cognitive domains. The division
in cognitive domains was made a priori, according to standard
neuropsychological practice and cognitive theory [18]. For the present
studywe focused on the domainswhich have previously been shown to
be affected in type 2 diabetes, namely the domains memory,
information-processing speed and attention and executive function
[1–3]. The domain ‘memory’was assessed by the forward and backward
digit span of theWechsler Adult Intelligence Scale – 3rd edition (WAIS-
III) [19], the Corsi Block-tapping Task [20], the Rey Auditory Verbal
Learning Test [21], the Location Learning Test [22] and the delayed recall
of theRey–Osterrieth Complex Figure Test [23]. The domain ‘information-
processing speed’ was assessed by the Trail-making Test Part A [24], the
Stroop Color-Word Test (part 1 and 2) [25] and the subtest Symbol
Digit Substitution of the WAIS-III. The domain ‘attention and executive
function’was assessed by the Trail-making Test Part B (ratio score) [24],
the Stroop Color-Word Test (part 3; ratio score), the Brixton Spatial
Anticipation Test [26], a letter ﬂuency test using the letters ‘N’ and
‘A’ and categoryﬂuency (animal naming) [27]. Furthermore, premorbid
level of intelligence (IQ) was estimated by the Dutch version of the
National Adult Reading Test [28]. Educational level was divided into
seven categories (1,b6 years of education; 2, 6 years; 3, 8 years; 4,
9 years; 5, 10–11 years; 6, 12–18 years and 7,>18 years). The tests
were administered in a ﬁxed order at the patients’ home by neuropsy-
chologists and neuropsychologists in training. The entire battery took
about 90 minutes to complete.
To assess possible selective loss to follow-up at the second NPA
we invited all non-participants and participants of the second NPA to
take part in the modiﬁed Dutch version of the Telephone Interview for
Cognitive Status (TICS-m), a 12 item screening instrument designed to
identify persons with dementia (maximum score 50) [29].
2.5. Timeline
The ﬁrst NPA took place three and a half years (mean 3.6±0.6
(±SD)) after screening and start of the intervention (Fig. 2). The second
NPA was performed 6.8 (±0.6) years after the screening, at the end of
the main ADDITION study, and 3.2 (±0.3) years after the ﬁrst NPA.
There was a mean interval of 4.6 (±3.6) months between the second
NPA and the last measurements of the main ADDITION study.
2.6. Risk factor assessment
At time of the NPAs body weight, height and blood pressure were
measured and BMIwas calculated. Systolic and diastolic blood pressures
were measured at the beginning and the end of the NPA with an
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Fig. 2. Study timeline.
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The Netherlands); measurementswere averaged. Demographic variables
andmedical history were recorded in a standardized interview. Smoking
was classiﬁed as current, past or never. ‘Any macrovascular event’ was
deﬁned as self-reported history of myocardial infarction, stroke or
surgery or endovascular treatment for carotid, coronary or peripheral
arterial disease.
Venous blood samples were drawn after an overnight fast to
determine HbA1c and total cholesterol. HbA1c was analyzed by
DCCT aligned ion-exchange high-performance liquid chromatography
using Menarini 8160 (A.Menarini Diagnostics, Florence, Italy). Lipids
were measured using standard enzymatic techniques using a Beckman
LX-20 (BeckmanCoultier inc., USA) until November 2008 and thereafter
a Roche Hitachi Modular P (Roche Diagnostics, USA). Because the
second NPA was not performed simultaneously with the close-out
of the intervention, we reassessed some risk factors (i.e. blood
pressure, height, weight) during the NPA.2.7. Analysis
Non-parametric data and proportions were analyzed respectively
with Wilcoxon test and McNemar test for changes over time and
Mann–Whitney test and Chi-square test for differences between
groups. Normally distributed continuous data on risk factors levels
were analyzed with multi-level linear regression analyses.
Raw test scores at ﬁrst and second NPA were standardized into
z-scores per test, using the pooled mean of the ﬁrst NPA scores of
the reference group. The individual's z-score reﬂects the number
of standard deviations a measurement deviates from the mean of
this group. The z-score of each domain was calculated by averaging the
test z-scores comprising that domain. In between group comparisons,
a mean difference in z-score below 0.2 is considered a small, between
0.2 and 0.8 a medium and above 0.8 a large effect [17]. The primary
outcome measure was deﬁned a priori, as themean difference between
the intensive treatment group and the routine care group in the com-
posite z-score of the domains memory, information-processing speed
and attention and executive function. These three domainswere selected
because they are most consistently affected in type 2 diabetes [1,3]. The
z-score on each of the separate domains was the secondary outcome
measure. For the ﬁrst NPA we calculated the z-scores per diabetic
group compared to the reference group and the difference between
the diabetic groups. To asses cognitive decline from the ﬁrst to the
second NPA we calculated a mean change over time per group and
a difference between the groups in change over time. Again the perfor-
mance of the non-diabetic group served as reference. Analyses were
done with multi-level linear regression analyses to take into account
the cluster-randomization at the general practice level. Analyses
for differences between groups were adjusted for IQ-score as the
reference group had a higher premorbid estimated intelligence.
The change over time was additionally adjusted for time between
the end of the intervention and the second NPA.3. Results
3.1. Study population
For the reference group 75 participants without diabetes underwent
the ﬁrst NPA. Six were excluded after the ﬁrst NPA, because they were
discovered to meet an exclusion criterion at the standardized face to
face interview, leaving 69 controls for the analyses. The mean age of
this group was 63 years, 48% were male and the mean IQ was 104.
Further characteristics have been described elsewhere [2]. As this
group acted as reference group, their mean z-scores at the ﬁrst NPA
were zero. At the second NPA two participants from the reference
group had died, one could not be contacted, nine declined to participate
and two had developed a fasting glucose above 7.0 mmol/L (Fig. 1). The
decline on the composite score over the three years was−0.07 (95%-CI
−0.14 to 0.01).
From the intensive treatment group 101 patients underwent the
ﬁrst NPA. Fourwere excluded after checking the results of the interview
against the exclusion criteria, leaving 97 patients for the ﬁrst analyses.
From the routine care group 96 patients were examined of which ten
were excluded, leaving 86 patients for the analyses. At the second
NPA 24 patients from the intensive treatment group declined to
participate and two patients could not be contacted. In the routine
care group two patients had died and 20 patients declined to participate
(Fig. 1). The second NPA was performed between February 2009 and
September 2010, with a mean interval of 3.2±0.3 years after the ﬁrst
NPA. Participants and non-participants at the second NPA did not differ
with respect to age (63.2 vs 62.8 years; p=0.69), sex (53.4% vs. 58.9%
male; p=0.47) and estimated premorbid IQ (97.4 vs 99.2; p=0.53),
but cognitive performance at the ﬁrst NPA differed with a mean
difference on the composite z-score of −0.18 (95%-CI −0.31 to
−0.04; participants are reference). The TICS-m was obtained in
34 of the 58 surviving non-participants (58.6%) and in 143 of the
192 participants at the second NPA (74.5%).
Within each of the three groups no difference was found between
participants and non-participants at the second NPA with respect
to age, sex and estimated premorbid IQ. For participants and
non-participants at the second NPA from the reference group
both the composite score of the ﬁrst NPA (0.03±0.4 vs −0.2±
0.6) and the TICS-score at follow-up (37.4±3.8 vs 35.0±4.4)
were comparable. In the intensive treatment group participants
of the second NPA scored higher than non-participants on the
composite score of the ﬁrst NPA (−0.2±0.5 vs −0.6±0.8), but
TICS-scores at follow-up were similar (35.1±4.7 vs 33.1±5.8). In
the routine care group the composite z-scores of the ﬁrst NPA
were comparable (−0.2±0.5 vs −0.2±0.5), but the TICS-score
at follow-up was slightly lower in those participating at the second
NPA (34.8±4.4 vs 37.8±5.4).
Among the whole group of non-participants, those participating in
the TICS (n=34) did not differ from those that did not perform a TICS
(n=26) with respect to age (63.7±5.0 vs 62.4±6.7; p=0.40), sex
(54.5% vs 52% male; p=0.85), estimated premorbid IQ (99.9±19.1
Table 1
Patient characteristics of diabetic patient groups.
Intensive treatment group Routine care group p-values
Baseline First NPA Finala Baseline First NPA Finala Group
difference
ﬁrst NPA
Group
difference
ﬁnal
Difference in
change from ﬁrst
NPA to ﬁnal
N 97 71 86 64
Sex (% males) 57.7 62.0 64.3 62.5 0.37 0.91
Age (years) 59.3±5.6 62.9±5.6 66.0±5.7 59.5±5.3 63.1±5.2 66.3±5.6 0.83 0.71
Educational level
(median (IQR))
4 (4–5) 4 (4–5) 5 (4–5) 5 (4–5) 0.19 0.79
Estimated premorbid
intelligence
95.2±19.4 96.5±19.3 98.6±19.4 98.8±20.5 0.24 0.82
BMI (kg/m2) 31.4±4.9 30.8±4.8b 31.4±5.3 30.4±4.3 30.2±4.9 30.8±5.1 0.38 0.50 0.88
Systolic blood pressure
(mmHg)
164.7±22.8 140.7±20.7b 136.9±17.6 162.4±20.5 147.0±17.7b 148.4±19.4 0.08 b0.01 0.06
Diastolic blood pressure
(mmHg)
89.6±10.9 81.3±10.6† 75.9±8.5 89.8±9.3 82.7±10.2b 81.2±10.1 0.44 b0.01 b0.01
Use of antihypertensive
drugs (%)
25.8 89.7b 94.4 26.5 72.1b 78.1 b0.01 b0.01
Current smoking (%) 22.7 20.0 19.4 19.8 22.6 14.3 0.67 0.63
HbA1c (mmol/mol; %) 56.2±14.4;
7.3±1.3
43.4±4.5;
6.1±0.4b
44.2±4.9;
6.2±0.4
56.1±17.0;
7.3±1.6
45.9±5.8;
6.4±0.5b
47.2±6.3;
6.5±0.6
0.15 b0.01 0.99
Total cholesterol
(mmol/L)
5.5±1.1 3.9±0.8b 4.0±0.8 5.5±1.2 4.4±1.1b 4.3±0.8 b0.01 0.04 0.84
Use of lipid-lowering
medication (%)
16.5 91.8b 90.1 18.1 64.0b 81.3 b0.01 0.13
Any macrovascular event
(%)
13.4 13.4 17.6 11.6 16.3 21.9 0.58 0.66
Data are presented as mean±SD or percentage unless otherwise speciﬁed.
a Physical and laboratory measurements measured at end of intervention; medication use, smoking and ‘any macrovascular event’ assessed during second NPA.
b Signiﬁcant difference between baseline measurement and ﬁrst NPA.
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(mean difference composite z-score 0.02; 95%-CI −0.36 to 0.39;
participants are reference).
3.2. Patient characteristics
Table 1 shows the patient characteristics of the routine care and
intensive treatment group at baseline of the ADDITION-study, at
ﬁrst NPA and at the ﬁnal measurements. The groups were similar inTable 2
Raw test scores of the reference group and the two diabetes groups at the ﬁrst and second
Intensive
Cognitive domain Cognitive test First NPA
(n=97)
Memory WAIS-III Digit Span forward 49.1±21.
WAIS-III Digit Span backward 24.1±13.
Corsi Block-Tapping Test forward 37.3±10.
Corsi Block-Tapping Test backward 38.7±17.
RAVLT total trials 1–5 35.5±9.4
RAVLT delayed recall 6.6±2.6
RAVLT recognition 27.1±3.2
LLT total trails 1-5a 15.1±16.
LLT learning index 0.8±0.3
LLT delayed triala 1.5±3.0
Complex Figure Test -Delay 16.5±5.6
Information-processing speed Stroop Color Word Test Ia 48.1±7.1
Stroop Color Word Test IIa 62.7±10.
TMT Part A 48.2±20.
WAIS-III Digit Symbol 56.0±14.
Attention and executive functioning Stroop Color Word Test IIIa 115.8±29
TMT Part B 101.2±44
Letter ﬂuency (mean of N+A) 10.2±4.0
Category ﬂuency (animals) 29.9±8.1
Brixton Spatial Anticipation Testa 16.2±6.9
RAVLT, Rey Auditory Verbal Learning Test; LLT, Location Learning Test; TMT, Trail Making T
a Higher test scores reﬂect worse performance.age, sex and IQ. Both groups improved signiﬁcantly on blood
pressure, HbA1c and total cholesterol during the ﬁrst three
years. Although the risk factor levels in the intensive treatment
group decreased more, the differences between the groups were
not signiﬁcant, except for total cholesterol. In both groups the
proportion of patients using antihypertensive and lipid-lowering
medication increased. Over the next three years the group difference
for total cholesterol remained and signiﬁcant between group differences
developed for blood pressure and HbA1c.examination (mean±SD).
treatment group Routine care group Reference group
Second NPA
(n=71)
First NPA
(n=86)
Second NPA
(n=64)
First NPA
(n=69)
Second NPA
(n=55)
2 40.4±24.4 50.3±23.4 42.8±24.0 57.3±27.8 47.7±19.4
6 23.0±18.5 24.9±16.1 25.6±19.5 29.3±18.7 27.9±18.1
5 35.7±12.2 39.0±13.7 41.1±11.8 37.9±12.4 39.7±13.1
1 35.3±14.7 36.9±15.4 38.2±16.1 40.8±15.3 41.3±15.4
41.1±11.8 36.1±8.3 41.0±10.2 41.3±10.6 46.6±11.1
8.3±3.5 6.9±2.7 8.1±3.0 7.8±3.1 10.0±3.3
28.5±2.2 27.6±2.5 28.5±2.2 28.4±1.6 29.0±1.4
7 25.4±21.5 15.7±17.7 23.6±18.9 15.9±20.8 15.6±18.1
0.6±0.3 0.7±0.3 0.6±0.3 0.8±0.3 0.7±0.3
2.6±4.9 1.4±3.0 1.9±3.3 1.5±3.0 5.7±12.4
16.5±6.3 16.6±5.4 16.2±5.9 19.4±5.2 18.6±6.4
50.2±8.4 46.4±8.1 50.1±11.6 44.9±8.5 47.3±9.0
5 62.3±10.6 62.6±10.4 65.9±13.2 59.9±12.9 61.2±13.7
7 41.5±11.8 42.8±15.5 43.4±17.0 42.1±17.1 39.5±16.5
7 55.6±17.4 59.6±14.3 57.0±15.5 61.8±17.0 64.3±16.6
.4 110.8±27.1 108.9±24.6 110.3±29.3 105.4±37.2 107.6±39.0
.9 93.5±39.4 102.2±48.7 96.5±50.2 89.7±29.2 81.6±29.4
11.2±4.9 10.1±4.7 10.9±4.8 11.8±4.4 12.4±3.9
30.0±9.4 31.4±8.5 32.4±9.1 34.5±8.8 35.5±8.8
17.6±5.6 16.2±5.8 17.3±5.7 14.6±5.4 16.4±5.2
est; WAIS-III, Wechsler Adult Intelligence Scale – Third edition.
Table 3
Mean difference per group compared to the reference group without diabetes in cognitive domain z-scores ﬁrst NPA and difference between the groups corrected for estimated
premorbid intelligence (95%-CI).
Intensive treatment group (n=97) Routine care group (n=86) Difference between groups
Composite score −0.15 (−0.31 to −0.01) −0.15 (−0.31 to −0.01) 0.00 (−0.16 to 0.16)
Memory −0.11 (−0.27 to 0.04) −0.17 (−0.33 to −0.01) 0.06 (−0.09 to 0.21)
Information-processing speed −0.19 (−0.42 to 0.03) −0.04 (−0.27 to 0.18) −0.15 (−0.36 to 0.06)
Attention and executive function −0.13 (−0.42 to 0.15) −0.19 (−0.48 to 0.09) 0.06 (−0.21 to 0.33)
Composite score was the primary outcome measure. Secondary analyses were done for the separate domains. Negative z-score indicates worse performance.
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Raw test scores of the reference group and the two diabetes groups
at the ﬁrst and second examination are presented in Table 2. At the
ﬁrst NPA there was no difference between the groups with respect to
the primary cognitive outcome measure (mean difference composite
z-score 0.00; 95%-CI −0.16 to 0.16) (Table 3). Similar results were
found in secondary analyses for the separate domains with mean
differences ranging from −0.15 to 0.06 (Table 3). In the following
three years the patients showed a slight decline in cognition (mean
change composite z-score intensive treatment: -0.14 (−0.23 to 0.06);
routine care: -0.02 (−0.12 to 0.07)). The mean difference between
the groups in change over time for the composite score was −0.12
(−0.24 to 0.01) (Table 4). Secondary analyses on the separate domains
showed mean differences between the groups in change over time
between −0.22 to 0.09 (Table 4).
4. Discussion
In this studywith cognitive assessments after three and six years of
intensive treatment we could not show a positive effect above routine
care on cognitive functioning in patients with screen-detected type 2
diabetes. After the ﬁrst three years of treatment both diabetic groups
had similar but modest decrements compared to the non-diabetic
reference group. Over the next three years cognitive decline in the
diabetic groups was within the range of the reference group and
did not differ between the treatment arms.
To the best of our knowledge, this was the ﬁrst study that compared
the effect of six years of intensive multifactorial treatment with routine
care on cognition in screen-detected type 2 diabetes. Strengths of our
study are the extensive NPA, which was performed in a substantial
number of patientswith type 2 diabetes, and the longitudinal assessment
of cognition over a period of three years. Moreover, treatment could be
initiated at an early stage of type 2 diabetes. A limitation of our study is
the timing of the NPAs. We were not able to perform a NPA at baseline.
As a result we may have missed a change in cognition in the ﬁrst three
years of treatment. Nevertheless, there is no indication that the groups
differed in cognition at baseline, as theywere comparable in demographic
variables and IQ. The secondNPA and theﬁnalmeasurements of themain
ADDITION study were not administered simultaneously; however we
found no differences in the contrast in risk factors between the
groups at the two time points (data not shown). Other potential
limitations are possible selection bias at the ﬁrst NPA and possible
selective attrition during follow-up. Although the lost to follow upTable 4
Mean change over time in z-scores per group and difference in change over time between
Intensive treatment group
(n=71)
Composite score −0.14 (−0.23 to −0.06)
Memory −0.27 (−0.38 to −0.15)
Information-processing speed −0.05 (−0.17 to 0.07)
Attention and executive function −0.15 (−0.28 to −0.02)
Composite score was the primary outcome measure. Secondary analyses were done for the
a Adjusted for time between end of intervention and second NPA and estimated premorwas random and equally divided over the two treatment groups it
might have led to an over- or underestimation of the cognitive
functioning in one of the groups. The latter we examined with
the TICS-m, which demonstrated no differences in cognitive
functioning between participants and non-participants.
We previously reported that this population of screen-detected type
2 diabetes patients has mild cognitive decrements compared to people
without diabetes (effect sizes up to −0.2) [2]. Other cross-sectional
studies found similar results with respect to impaired cognitive function
in type 2 diabetes (effect sizes−0.3 to−0.6) [1]. In agreementwith our
study, recent longitudinal studies demonstrated that the rate of
cognitive decline in people with type 2 diabetes is generally slow
and only slightly exceeds the rate of decline in normal ageing
[3,30]. Probably, the process of cognitive decrements starts already in
(pre-)diabetic stages and the decrements progress only slowly thereafter.
Nevertheless, people with type 2 diabetes are overrepresented in the
subgroup of individuals that show frank cognitive decline or progress to
dementia [4–6]. These recent insights into the course of development of
cognitive decrements in people with type 2 diabetes do have important
implications for future intervention studies. Possibly such studies should
target the prevention of accelerated decline rather than average change
in cognition across a whole population of patients, but this will require
much larger study cohorts.
The intensive treatment in the main ADDITION-study resulted in a
small but signiﬁcant difference in change frombaseline for several risk
factors relative to routine care. In addition the intensive multifactorial
treatment was associated with a non-signiﬁcant 17% reduction of
cardiovascular events. We did not ﬁnd an effect of the six years
intervention on cognitive functioning. In addition to the relative
benign course of cognitive decline in the patients with diabetes,
this might be caused by the well-controlled cardiovascular risk
factors in both groups. At time of the ﬁrst NPA, risk factor levels
in our participants had already dropped signiﬁcantly in both the
routine care and the intensive treatment group, with minor differences
between these groups. After six years of treatment the differences
between the groups did become signiﬁcant. Both groups however
were treated well, which is probably the result of the high standard
of care in general practice for patients with type 2 diabetes. In The
Netherlands routine care improved by a new evidence based guideline
in 2006 [16].
Some previous studies did report effects of improved glycemic
control on cognitive functioning in people with type 2 diabetes [9,10].
However, these studies did not include a non-diabetic reference group,
the follow-up time in these studies was short (≤24 weeks) and thethe groups (95%-CI).
Routine care group
(n=64)
Adjusted difference between
groups in change over timea
−0.02 (−0.12 to 0.07) −0.12 (−0.24 to 0.01)
−0.05 (−0.17 to 0.07) −0.22 (−0.38 to −0.05)
−0.13 (−0.27 to 0.00) 0.09 (−0.09 to 0.26)
0.07 (−0.07 to 0.21) −0.21 (−0.41 to −0.02)
separate domains. Negative z-score indicates worse performance.
bid intelligence.
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mol (7.6%)). Because of the interval between start of treatment at
baseline of the ADDITION study and ﬁrst NPA we may have missed
improvement of cognition with lowering of HbA1c. Furthermore,
other studies indicate that mid-life hypertension might affect cognitive
functioning later in life [31] and that hypertension is one of the factors
involved in diabetes-associated cognitive decline [32]. Therefore strict
control of blood pressure inmid-lifemight be away to prevent cognitive
decline. In our study the intensive treatment protocol resulted in a
signiﬁcantly lower blood pressure at close-out compared to routine
care, but our follow-up time may have been too short to result in a
signiﬁcant effect on cognition.
It should be emphasized that cognitive functioning in our study
population was within the range of normal ageing. The observed
treatment effects on cognitive functioning may therefore not be
generalizable to prevention of pathological cognitive decline, such as
(early) dementia.
In conclusion, patients with screen-detected type 2 diabetes did
not suffer from accelerated decline compared to participants without
diabetes. In addition, we could not demonstrate that intensive
multifactorial treatment had a beneﬁcial effect on decline of cognitive
functioning above routine care.
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